Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers

LUNG 11.19.2024

Full Press ReleaseSEC FilingsOur LUNG Tweets

About Gravity Analytica

Recent News

  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.21.2024 - Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
  • 11.20.2024 - Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.17.2025 - 144 Report of proposed sale of securities

Two New Programs Aim to Improve Awareness and Support for Patients with Severe COPD/Emphysema

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 19, 2024--Pulmonx Corporation(Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, and theAmerican Lung Associationare continuing their ongoing collaboration with two new programs aimed at supporting patients with severe COPD and emphysema.

Building on their successful partnership, the two organizations will launch new resources to educate patients and healthcare providers on innovative treatment options like the Zephyr® Endobronchial Valve, a minimally invasive therapy for advanced COPD/emphysema. According to theWorld Health Organization(WHO), COPD remains the third leading cause of death worldwide, with millions of patients struggling to breathe and maintain quality of life despite medical management.

As part of this collaboration,Pulmonxand theLung Associationwill introduce two new programs to empower patients and clinicians:

  1. InNovember 2024, the Lung Association’s EACH BREATH blog will feature stories from two patients with diverse backgroundswhoreceived endobronchial valve (EBV) treatment, sharing their journeys, decisions, and insights on life before and after the procedure.
  2. In January, a leading pulmonologist will host an “Ask the Expert” session on theLung Association'ssupported “Living with COPD”and “Living with Lung Disease” online communities. The Q&A will be archived on the platform as a lasting resource for patients exploring severe COPD/emphysema treatment options.

“We are excited to continue our partnership with theAmerican Lung Associationand together build awareness about the life-changing benefits of the Zephyr Valve therapy,” saidSteve Williamson, CEO ofPulmonx. “COPD is a debilitating disease. We want patients and their physicians to know that there are treatment options available to help them breathe easier and live more active lives.”

“A COPD diagnosis can be devastating for an individual and their family to hear, but thankfully there are treatment options available to help improve the lives of people living with this disease,” saidDeb Brown, Chief Mission Officer of theAmerican Lung Association. “An important part of living with COPD is being educated on the latest treatments and guidelines. TheAmerican Lung Associationis proud to partner withPulmonxto further our commitment to support those affected by COPD and offer a variety of resources and information about the disease.”

The Lung Associationcollaboration will also build upon the existing educational content available to both patients and healthcare professionals, ensuring that those affected by COPD can make informed decisions about their treatment options.

About theAmerican Lung Association

TheAmerican Lung Associationis the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of theAmerican Lung Associationis focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about theAmerican Lung Association, which has a 4-star rating from Charity Navigator and is a Platinum-Level GuideStar Member, call 1-800-LUNGUSA (1-800-586-4872) or visit:Lung.org.To support the work of theAmerican Lung Association, find a local event atLung.org/events.

About Zephyr Valves

The Zephyr Endobronchial Valve is a minimally invasive treatment option for severe COPD/emphysema. Zephyr Valves are placed via bronchoscopy to block off a diseased portion of the lung to prevent air from getting trapped and reduce hyperinflation, which allows the healthier lung tissue to expand and take in more air. This results in patients being able to breathe easier, be less short of breath, and have an improvement in their quality of life.1National and global treatment guidelines for COPD include Endobronchial Valves like Zephyr Valves as a recommended treatment option for patients with severe COPD/emphysema, with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) giving valves an ‘Evidence A’ rating. More than 40,000 patients have been treated with Zephyr Valves worldwide.

AboutPulmonx Corporation

Pulmonx Corporation(Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraXTM Platform and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPDwhodespite medical management are still profoundly symptomatic.Pulmonxreceived FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visitwww.Pulmonx.com.

References1Criner G et al. Am J Respir Crit Care Med. 2018; 198 (9): 1151–1164.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241119814005/en/

Media Contact:Marcee Maroneymmaroney@pulmonx.com

Source:Pulmonx Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com